Substituted xanthine derivatives

Patent metadata

Field	Value
Publication number	US-9493463-B2
Application number	US-201514713423-A
Country	US
Kind code	B2
Filing date	May 15, 2015
Priority date	Feb 29, 2008
Publication date	Nov 15, 2016
Grant date	Nov 15, 2016

Abstract

This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.

First claim

What is claimed is:

1. A compound of Formula B:

or a pharmaceutically acceptable salt thereof, wherein:
each of R 1 and R 2 is independently selected from —CH 3 and —CD 3 ;
R 5 is hydrogen or deuterium;
each Z 3 is hydrogen or deuterium;
each Z 4 is hydrogen or deuterium;
each Z 5 is hydrogen or deuterium;
either (a) Y 1 is OH, and Y 2 is hydrogen or deuterium, or (b) Y 1 and Y 2 are taken together with the carbon to which they are attached to form C═O; and
the deuterium incorporation at each designated deuterium atom is at least 90%.

2. The compound of claim 1 , wherein R 5 is deuterium.

3. The compound of claim 2 , wherein each Z 3 , Z 4 and Z 5 is hydrogen and R 1 is —CD 3 .

4. The compound of claim 1 , wherein each Z 3 , Z 4 and Z 5 is hydrogen.

5. The compound of claim 1 , wherein each Z 3 , Z 4 and Z 5 is deuterium.

6. The compound of claim 1 , wherein R 1 and R 2 are each —CD 3 .

7. The compound of claim 1 , wherein Y 1 and Y 2 are taken together with the carbon to which they are attached to form C═O.

8. The compound of claim 1 , wherein Y 1 and is OH, and Y 2 is hydrogen or deuterium.

9. A compound of Formula I:

or a pharmaceutically acceptable salt thereof, selected from the following:

Compound
R 1
R 2
R 3
R 4
Y 1
Y 2

103
CD 3
CD 3
CD 3
(CD 2 ) 4
taken together as ═O

104
CH 3
CH 3
CD 3
(CD 2 ) 4
taken together as ═O

105
CD 3
CH 3
CD 3
(CD 2 ) 4
taken together as ═O

106
CH 3
CD 3
CD 3
(CD 2 ) 4
taken together as ═O

107
CH 3
CH 3
CD 3
† CD 2 (CH 2 ) 3
taken together as ═O

108
CH 3
CH 3
CD 3
† (CD 2 ) 3 CH 2
taken together as ═O

109
CD 3
CH 3
CD 3
† CD 2 (CH 2 ) 3
taken together as ═O

110
CD 3
CH 3
CD 3
† (CD 2 ) 3 CH 2
taken together as ═O

111
CH 3
CD 3
CD 3
† CD 2 (CH 2 ) 3
taken together as ═O

112
CH 3
CD 3
CD 3
† (CD 2 ) 3 CH 2
taken together as ═O

113
CD 3
CD 3
CD 3
† CD 2 (CH 2 ) 3
taken together as ═O

114
CD 3
CD 3
CD 3
† (CD 2 ) 3 CH 2
taken together as ═O

118
CD 3
CD 3
CD 3
† CD 2 (CH 2 ) 3
OH
H

119
CD 3
CH 3
CD 3
† CD 2 (CH 2 ) 3
OH
H

120
CH 3
CD 3
CD 3
† CD 2 (CH 2 ) 3
OH
H

121
CH 3
CH 3
CD 3
† CD 2 (CH 2 ) 3
OH
H

122
CD 3
CD 3
CD 3
(CD 2 ) 4
OH
H

123
CD 3
CH 3
CD 3
(CD 2 ) 4
OH
H

124
CH 3
CD 3
CD 3
(CD 2 ) 4
OH
H

125
CH 3
CH 3
CD 3
(CD 2 ) 4
OH
H

126
CD 3
CD 3
CD 3
† (CD 2 ) 3 CH 2
OH
H

127
CD 3
CH 3
CD 3
† (CD 2 ) 3 CH 2
OH
H

128
CH 3
CD 3
CD 3
† (CD 2 ) 3 CH 2
OH
H

129
CH 3
CH 3
CD 3
† (CD 2 ) 3 CH 2
OH
H

130
CD 3
CD 3
CH 3
(CH 2 ) 4
OH
D

131
CD 3
CH 3
CH 3
(CH 2 ) 4
OH
D

132
CH 3
CD 3
CH 3
(CH 2 ) 4
OH
D

133
CH 3
CH 3

Assignees

• Concert Pharmaceuticals Inc

Inventors

• Tung Roger D
• Liu Julie F
• Harbeson Scott L

Classifications

• A61P7/02

  Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P3/06

  Antihyperlipidemics · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P37/02

  Immunomodulators · CPC title